Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in chronic inducible cold urticaria refractory to H1-antihistamines
2020-003756-33Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cold urticaria (CU) comparing Dupilumab with Placebo (2 arms). Started Nov 2020; status: completed.
02
Drugs
03
Conditions
Cold urticaria (CU)
Beyond the preview
Go deeper on 2020-003756-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003756-33.